Abbvie Inc Stock Fair Value Calculation – AbbVie Drug Shows Promising Results in Phase 2 Study for Treating Lung Cancer
December 11, 2023
🌧️Trending News
ABBVIE ($NYSE:ABBV): AbbVie Inc. is a research-driven and publicly traded biopharmaceutical company based in North Chicago, Illinois. The company focuses on discovering, developing, and selling innovative medicines around the world for many human diseases, including cancer. Recently, AbbVie has announced promising findings from a Phase 2 study of their lung cancer medication. The multi-center, randomized, open-label study assessed the safety and efficacy of AbbVie’s drug, Rova-T, in combination with chemotherapy in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).
The study found that the combination of Rova-T and chemotherapy proved to be effective for treating SCLC. The drug shows great promise in treating the disease, and AbbVie is now working on conducting Phase 3 clinical trials to continue to assess the safety and efficacy of Rova-T. If successful, Rova-T could become a new treatment option for patients with SCLC.
Share Price
On Wednesday, ABBVIE INC stock opened at $138.0 and closed at $138.5, up by 0.3% from the previous closing price of 138.1. The drug, which is still undergoing clinical trials, was found to be well tolerated and to have a favorable safety profile in the phase 2 study. Additionally, it showed promising signs of efficacy, demonstrating that further trials may be successful. The encouraging results of the study have boosted the stock of ABBVIE INC and instilled confidence in its investors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbvie Inc. More…
| Total Revenues | Net Income | Net Margin |
| 55.14k | 6.5k | 13.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbvie Inc. More…
| Operations | Investing | Financing |
| 25.54k | -623 | -24.8k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbvie Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 135.37k | 122.47k | 7.29 |
Key Ratios Snapshot
Some of the financial key ratios for Abbvie Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.7% | 7.8% | 17.9% |
| FCF Margin | ROE | ROA |
| 45.0% | 48.0% | 4.6% |
Analysis – Abbvie Inc Stock Fair Value Calculation
At GoodWhale, we conducted an analysis of ABBVIE INC‘s fundamentals. Upon completing our analysis, we found that the intrinsic value of an ABBVIE INC share is around $146.5, calculated using our proprietary Valuation Line. Currently, the stock is being traded at $138.5, making it a fair price that is undervalued by 5.5%. More…
Peers
AbbVie Inc is a global, research-based biopharmaceutical company formed in 2013. AbbVie combines the focus and passion of a leading-edge biotech with the experience and breadth of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
Kwang Dong Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceuticals Co Ltd, Vivesto AB are all competitors of AbbVie Inc.
– Kwang Dong Pharmaceutical Co Ltd ($KOSE:009290)
Kwang Dong Pharmaceutical Co Ltd is a South Korean company that manufactures and sells pharmaceutical products. The company has a market cap of 233.75 billion as of 2022 and a return on equity of 19.33%. Kwang Dong Pharmaceutical Co Ltd manufactures a wide range of pharmaceutical products, including antibiotics, anti-inflammatory drugs, and cardiovascular drugs. The company also has a research and development department that is responsible for developing new drugs and formulations.
– Jiangsu Hengrui Pharmaceuticals Co Ltd ($SHSE:600276)
Jiangsu Hengrui Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that engages in the research, development, manufacture, and sale of chemical and biological drugs in China and internationally. The company has a market cap of 248.78 billion as of 2022 and a return on equity of 6.72%. Jiangsu Hengrui Pharmaceutical Co., Ltd. is headquartered in Lianyungang, China.
– Vivesto AB ($OTCPK:OASMY)
Vivesto AB is a Swedish company that provides financial technology solutions. The company has a market capitalization of 32.61 million as of 2022 and a return on equity of -9.39%. Vivesto’s products and services include online banking, mobile banking, and payments solutions. The company serves retail, corporate, and institutional clients.
Summary
ABBVIE Inc. (NYSE: ABBV) is a research-based biopharmaceutical company that develops treatments for various medical conditions including cancer, HIV/AIDS, and Alzheimer’s disease. Recently, the company reported positive results from a Phase 2 clinical trial of its investigational lung cancer drug.
The results of the trial showed that the drug was safe and well-tolerated among patients, further pointing to its potential efficacy. Investors are viewing this news positively, as there is now more reason to believe the drug may gain regulatory approval and enter the market in the future.
